Login to Your Account

With Shire's $1.6B Buyout, TKT On 'Verge Of Becoming Great'

By Randall Osborne

Monday, April 25, 2005


It seemed bound to happen.

Getting ready to sign a partner in Europe for Dynepo (epoetin delta), its version of erythropoietin, Transkaryotic Therapies Inc. had been bracing an eager market for data from the pivotal Phase III trial with another therapy - iduronate-2-sulfatase for Hunter syndrome, expected in the second half of 2005, with Phase I/II data due about the same time from the open-label Phase I/II trial testing of yet another enzyme-replacement therapy, GA-GCB in Gaucher's disease.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription